S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
The 32-Second Options Trading "Training Video" Retirees Can't Get Enough Of (Ad)
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Former Deutsche Bank Co-CEO Anshu Jain dies
High oil prices help Saudi Aramco earn $88B in first half
Sell every Stock except ONE (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
The 32-Second Options Trading "Training Video" Retirees Can't Get Enough Of (Ad)
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Former Deutsche Bank Co-CEO Anshu Jain dies
High oil prices help Saudi Aramco earn $88B in first half
Sell every Stock except ONE (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
The 32-Second Options Trading "Training Video" Retirees Can't Get Enough Of (Ad)
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Former Deutsche Bank Co-CEO Anshu Jain dies
High oil prices help Saudi Aramco earn $88B in first half
Sell every Stock except ONE (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
The 32-Second Options Trading "Training Video" Retirees Can't Get Enough Of (Ad)
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Former Deutsche Bank Co-CEO Anshu Jain dies
High oil prices help Saudi Aramco earn $88B in first half
Sell every Stock except ONE (Ad)
NYSE:TEVA

Teva Pharmaceutical Industries - TEVA Price Target & Analyst Ratings

$11.21
+0.12 (+1.08%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$11.04
$11.32
50-Day Range
$6.86
$11.21
52-Week Range
$6.78
$11.34
Volume
12.48 million shs
Average Volume
19.24 million shs
Market Capitalization
$12.37 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.67

Teva Pharmaceutical Industries Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 8 Analyst Ratings

Consensus Analyst Price Target

$10.67
-4.85% Downside
High Prediction$13.00
Average Prediction$10.67
Low Prediction$7.00
TypeCurrent
8/14/21 to 8/14/22
1 Month Ago
7/15/21 to 7/15/22
3 Months Ago
5/16/21 to 5/16/22
1 Year Ago
8/14/20 to 8/14/21
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
Hold
4 Hold rating(s)
5 Hold rating(s)
3 Hold rating(s)
5 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$10.67$10.71$11.20$10.86
Predicted Upside-4.85% Downside21.23% Upside21.02% Upside10.30% Upside
Get Teva Pharmaceutical Industries Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter.


TEVA Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TEVA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Teva Pharmaceutical Industries Stock vs. The Competition

TypeTeva Pharmaceutical IndustriesMedical CompaniesS&P 500
Consensus Rating Score
2.25
2.71
2.50
Consensus RatingHoldBuyHold
Predicted Upside-4.85% Downside719.23% Upside13.85% Upside
News Sentiment RatingNeutral News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
1294
67.75%
Underperform Votes
616
32.25%
Avg. Outperform Votes
166
66.67%
Avg. Underperform Votes
83
33.33%
Avg. Outperform Votes
840
68.74%
Avg. Underperform Votes
382
31.26%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/5/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$10.00 ➝ $13.00+28.46%
8/2/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral$9.00 ➝ $10.00+4.71%
6/13/2022UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$10.00+26.74%
5/4/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underweight$11.00 ➝ $7.00-18.60%
4/5/2022Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeEqual Weight ➝ Overweight$11.00 ➝ $13.00+31.45%
3/25/2022Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$11.00+34.64%
1/27/2022Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
10/28/2021Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
7/29/2021Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight$12.00 ➝ $11.00+10.11%
3/14/2021JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold$10.00-7.32%
11/24/2020Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform
11/6/2020BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Perform$13.00 ➝ $11.00+27.76%
8/6/2020SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform$13.00 ➝ $14.00+10.58%
6/1/2020SunTrust Banks
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$11.00 ➝ $16.00+27.69%
5/8/2020Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Chen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral
4/24/2020Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral
4/2/2020Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetUnderweight$13.00 ➝ $8.00-3.38%
2/24/2020Edward Jones
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeHold ➝ Sell
2/12/2020Cfra
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold$11.00 ➝ $13.00-3.48%
10/16/2019Gabelli
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
9/12/2019Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral
(Data available from 8/14/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












TEVA Price Target - Frequently Asked Questions

What is Teva Pharmaceutical Industries's consensus rating and price target?

According to the issued ratings of 8 analysts in the last year, the consensus rating for Teva Pharmaceutical Industries stock is Hold based on the current 1 sell rating, 4 hold ratings and 3 buy ratings for TEVA. The average twelve-month price prediction for Teva Pharmaceutical Industries is $10.67 with a high price target of $13.00 and a low price target of $7.00. Learn more on TEVA's analyst rating history.

Do Wall Street analysts like Teva Pharmaceutical Industries more than its competitors?

Analysts like Teva Pharmaceutical Industries less than other Medical companies. The consensus rating for Teva Pharmaceutical Industries is Hold while the average consensus rating for medical companies is Buy. Learn more on how TEVA compares to other companies.

Do MarketBeat users like Teva Pharmaceutical Industries more than its competitors?

MarketBeat users like Teva Pharmaceutical Industries more than other Medical companies. 67.75% of MarketBeat users gave Teva Pharmaceutical Industries an outperform vote while medical companies recieve an average of 66.67% outperform votes by MarketBeat users.

Is Teva Pharmaceutical Industries being upgraded by Wall Street analysts?

Over the previous 90 days, Teva Pharmaceutical Industries's stock had 2 upgrades by analysts.

Does Teva Pharmaceutical Industries's stock price have much upside?

According to analysts, Teva Pharmaceutical Industries's stock has a predicted upside of 18.04% based on their 12-month price targets.

What analysts cover Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries has been rated by Bank of America, The Goldman Sachs Group, and UBS Group in the past 90 days.


Stock Ratings Reports and Tools

This page (NYSE:TEVA) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.